DOSEGUY

Metatrutide

guinea pig

Also seen as: GLP-4, GLP-4 Metatrutide

The Dose Guy’s verdict
Sep 1, 2026
0 sources

I can’t recommend something that doesn’t exist in the scientific literature. Metatrutide is a name sold by peptide vendors, marketed as a next-generation triple agonist, and backed by zero published pharmacology. No trials, no animal studies, no receptor-binding data, no characterization of what the compound actually is. The name rides the wave that retatrutide built, and that’s the entire story. If you want a triple agonist with real data, run retatrutide.

Would I take it?No idea what's in the vial.

What it is

Nobody knows, and that’s the problem. Vendor listings call metatrutide a triple agonist at GLP-1, GIP, and glucagon, the same receptor profile as retatrutide, and market it under the label “GLP-4.” There’s no GLP-4 receptor in human physiology. That’s branding, not biology. The PubMed corpus contains no article identifying metatrutide as a pharmacologic compound, no receptor assay, no animal model, no clinical observation. What’s in the vial could be a retatrutide analog, a blend, or something else entirely. Without published characterization, there’s no way to evaluate what you’re buying.

This is what happens when demand for a compound class outruns the science: vendors fill the gap with names and implied lineage, and the buyer assumes the risk.

What the research shows

No human trials. Zero. Everything below is animal or in-vitro work. Read it as “interesting,” not “evidence it works in you.”

There’s no research to summarize. The search turns up nothing:

No article in PubMed identifies metatrutide as a pharmacologic compound or investigational medicine.as of Aug 2026
No human trial, animal study, or in vitro receptor assay of metatrutide exists in the published literature.as of Aug 2026

Realistic protocols

There’s no protocol to write when nobody knows what’s in the vial. The vendor world lists doses that echo retatrutide’s range, which tells you what the marketing is modeled on, not what the compound does. If you insist on running it, the harm reduction starts before the needle: demand a third-party COA for anything you buy, and treat a vial with no independent analysis as unknown mass of unknown compound. Get bloodwork before and after, and know that you’ve got no reference point for what normal looks like. The better move is to run the thing metatrutide is imitating. Retatrutide has phase 3 data and years of community mileage.

Side effects

No human, animal, or cellular safety data exists:

unknownThe compound hasn’t been characterized in any published study. Every possible side effect is unknown because the compound itself is unknown.
unknownIf metatrutide is a retatrutide analog, the side profile may resemble the incretin class: GI disturbance, heart-rate elevation, nausea. But that’s a guess based on a marketing claim, not a data point.

Where to buy

No live listings from tracked vendors right now.